Home » Topics » BioWorld Science, Cardiovascular

BioWorld Science, Cardiovascular
RSS

Ironwood reports first-in-human results for cardiovascular disease candidate IW-1973

April 8, 2016

Ironwood Pharmaceuticals describes sGC activators

April 7, 2016

Bristol-Myers Squibb presents peroxidase inhibitors

April 4, 2016

Ubenimex awarded orphan drug designation in E.U. for PAH

March 29, 2016

Inactivating variants in ANGPTL4 are associated with lower risk of coronary artery disease

March 29, 2016

AstraZeneca's ticagrelor stroke study misses primary endpoint

March 23, 2016

Aralez resubmits Yosprala NDA

March 16, 2016

ANI to acquire Inderal LA assets from Cranford Pharmaceuticals

March 15, 2016

Vericel releases topline results from phase IIb study of ixmyelocel-T

March 11, 2016

Theravance successfully completes single-ascending-dose phase I trial of TD-0714

March 10, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...